EP0102404A1 - Novel polycyclic fused pyrazole compounds useful as antiinflammatory agents and preparation thereof - Google Patents

Novel polycyclic fused pyrazole compounds useful as antiinflammatory agents and preparation thereof Download PDF

Info

Publication number
EP0102404A1
EP0102404A1 EP82108105A EP82108105A EP0102404A1 EP 0102404 A1 EP0102404 A1 EP 0102404A1 EP 82108105 A EP82108105 A EP 82108105A EP 82108105 A EP82108105 A EP 82108105A EP 0102404 A1 EP0102404 A1 EP 0102404A1
Authority
EP
European Patent Office
Prior art keywords
methyl
pyrazole
fluorophenyl
compound
ethenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP82108105A
Other languages
German (de)
French (fr)
Inventor
Malcolm Rice Bell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STWB Inc
Original Assignee
Sterling Drug Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Drug Inc filed Critical Sterling Drug Inc
Priority to EP82108105A priority Critical patent/EP0102404A1/en
Publication of EP0102404A1 publication Critical patent/EP0102404A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems

Definitions

  • the present invention relates to novel polycyclic fused pyrazole compounds, useful as anti-inflammatory agents, and the preparation thereof.
  • Typical glucocorticoid activity is rarely found in structures which do not possess an intact steroid nucleus. Such activity is found in naturally occurring steroids such as cortisone, hydrocortisone and aldosterone, as well as numerous synthetic modifications thereof, all containing the intact steroid nucleus.
  • An example of a synthetic cortical steroid having high activity is a fluorophenylpyrazole derivative reported by Fried et al., J. Am. Chem. Soc. 85, 236 (1963), having the structure
  • the present invention relates to compounds having the formulas: wherein R and R' are lower-alkyl groups.
  • Said compounds can be used in a pharmaceutical composition for treating inflammation in mammals which comprises an anti-inflammatorily effective amount of said compound of Formula I or II and a pharmaceutically acceptable carrier.
  • One can reduce inflammation in a mammal by administering to said mammal an anti-inflammatorily effective amount of a compound of Formula I or II.
  • the invention also relates to an intermediate for use in the preparation of the compounds of Formulas I and II, said intermediate having the formula:
  • novel intermediate of Formula III is prepared from a known starting material, 5-ethenyl-4,4a,7,8-tetrahydro-4a-methyl-2(3H)-naphthalenone (cf. Bell et al. U.S. Patent 4,157,349, June 5, 1979) in accordance with the following reactions:
  • the trienone starting material is reacted with methyl formate in the presence of sodium methoxide in an inert solvent such as tetrahydrofuran to afford 5-ethenyl-3-hydroxymethylene-4,4a,7,8-tetrahydro-4a-methyl-2(3H)-naphthalenone, and the latter is then reacted with 4-fluorophenylhydrazine or an acid-addition salt thereof in the presence of acetic acid to give the compound of Formula III.
  • an inert solvent such as tetrahydrofuran
  • a small quantity of a free radical chain reaction inhibitor such as 1,2,3-benzenetriol (pyrogallol), may be added.
  • the lower-alkyl groups R and R' preferably have from one to four carbon atoms, including, for example, methyl, ethyl, propyl, isopropyl, butyl and isobutyl.
  • the compounds of Formulas I and II exhibit an endocrinological profile characteristic of compounds possessing glucocorticoid properties and systemic and/or topical anti-inflammatory activity; cf. R.H. Silber, The Biology of Anti-inflammatory Steroids, Annals of the New York Academy of Sciences, Vol. 82, Art. 4. pp. 821-828.
  • the compound of Formula I where R is methyl has also been found to possess oral glucocorticoid activity by the liver glycogen deposition test and anti-inflammatory activity by the a-tocopherol pouch test in rats.
  • test procedures used to determine the biological activities of the compounds of the invention were carried out as follows:
  • Glycogenic Activity Mature male rats were bilaterally adrenalectomized 5 days prior to the test. These rats were medicated orally with the test compound for 5 days. Seven hours after the last medication, the rats (which have been fasted overnight) were anesthetized with sodium pentobarbital and a portion of one lobe of the liver was removed and frozen on dry ice for subsequent glycogen determination.
  • the compounds of the invention can be formulated for topical application by solution of dispersion in a conventional pharmaceutically acceptable liquid, cream or ointment base.
  • the effective ingredient is preferably present in a concentration of 0.01% to 5.0% by weight.
  • the compounds of the invention can be formulated for oral administration in tablet or capsule form with conventional excipients.
  • the active ingredient is preferably present in an amount of 1 mg to 100 mg per unit dosage form.
  • the oil was purified by using high-performance liquid chromatography with 3.97 ethyl acetate-CH 2 Cl 2 followed by recrystallization from methanol to afford 10.98 g of diethyl 8-(4-fluorophenyl)-2,3,4,4a,5,6,ll,lla-octahydro-lla-methyl-8H-phenanthro-[2,3-c]pyrazole-4,4-dicarboxylate as a colorless solid, m.p. 133-135°C.
  • the PMR spectrum was consistent with the assigned structure.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

@ The compounds of the formulas
Figure imga0001
where R and R' are lower-alkyl possess glucocorticoid activity, and are prepared by reacting the compound of the formula with the appropriate dienophile.

Description

  • The present invention relates to novel polycyclic fused pyrazole compounds, useful as anti-inflammatory agents, and the preparation thereof.
  • Typical glucocorticoid activity is rarely found in structures which do not possess an intact steroid nucleus. Such activity is found in naturally occurring steroids such as cortisone, hydrocortisone and aldosterone, as well as numerous synthetic modifications thereof, all containing the intact steroid nucleus. An example of a synthetic cortical steroid having high activity is a fluorophenylpyrazole derivative reported by Fried et al., J. Am. Chem. Soc. 85, 236 (1963), having the structure
    Figure imgb0001
  • The present invention relates to compounds having the formulas:
    Figure imgb0002
    wherein R and R' are lower-alkyl groups. Said compounds can be used in a pharmaceutical composition for treating inflammation in mammals which comprises an anti-inflammatorily effective amount of said compound of Formula I or II and a pharmaceutically acceptable carrier. One can reduce inflammation in a mammal by administering to said mammal an anti-inflammatorily effective amount of a compound of Formula I or II.
  • The invention also relates to an intermediate for use in the preparation of the compounds of Formulas I and II, said intermediate having the formula:
    Figure imgb0003
  • One can prepare the compounds of Formulas I or II by reacting the compound of Formula III with a compound of the formula RCOCH=CHCOR or CH2=C(COOR')2, respectively.
  • The novel intermediate of Formula III is prepared from a known starting material, 5-ethenyl-4,4a,7,8-tetrahydro-4a-methyl-2(3H)-naphthalenone (cf. Bell et al. U.S. Patent 4,157,349, June 5, 1979) in accordance with the following reactions:
    Figure imgb0004
  • The trienone starting material is reacted with methyl formate in the presence of sodium methoxide in an inert solvent such as tetrahydrofuran to afford 5-ethenyl-3-hydroxymethylene-4,4a,7,8-tetrahydro-4a-methyl-2(3H)-naphthalenone, and the latter is then reacted with 4-fluorophenylhydrazine or an acid-addition salt thereof in the presence of acetic acid to give the compound of Formula III.
  • The preparation of a compound of Formula I by reacting the compound of Formula III with an unsaturated diketone of the formula RCOCH=CHCOR takes place by heating the reactants in an inert solvent at a temperature between about 50° and 150°C. Similarly, a compound of Formula II is prepared by heating III with a di-lower-alkyl methylenemalonate [CH2=C(COOR')2]. In order to suppress the tendency of the diene to polymerize, a small quantity of a free radical chain reaction inhibitor such as 1,2,3-benzenetriol (pyrogallol), may be added.
  • The lower-alkyl groups R and R' preferably have from one to four carbon atoms, including, for example, methyl, ethyl, propyl, isopropyl, butyl and isobutyl.
  • The compounds of Formulas I and II exhibit an endocrinological profile characteristic of compounds possessing glucocorticoid properties and systemic and/or topical anti-inflammatory activity; cf. R.H. Silber, The Biology of Anti-inflammatory Steroids, Annals of the New York Academy of Sciences, Vol. 82, Art. 4. pp. 821-828.
  • When the compounds of Formulas I and II are administered orally to rats they cause a significant depression in thymus weight, adrenal weight and body weight gain without a change in food consumption.
  • The compound of Formula I where R is methyl has also been found to possess oral glucocorticoid activity by the liver glycogen deposition test and anti-inflammatory activity by the a-tocopherol pouch test in rats.
  • The test procedures used to determine the biological activities of the compounds of the invention were carried out as follows:
    • Endocrine Profile: Mature female rats with an average body weight of 202 g and a body weight range of 15 g or less were medicated orally with test compound for 2 weeks. The test compound was prepared as a solution or suspension in 1% gum tragacanth or 0.75% methyl cellulose. On the day following the last medication, the rats were killed and the thymus and adrenal of each rat were removed, cleaned, and weighed. Body weights and food consumptions were also recorded.
    Anti-inflammatory Activity (a-tocopherol pouch test):
  • Male rats which weighed 120 g were selected for testing. A rapid subcutaneous injection of 25 mL of air was made between the scapulae of each rat. This resulted in the establishment of an airfilled pouch into which 0.5 mL of dl-a-tocopherol was injected. The test compound was administered in daily oral doses for 7 days beginning on the day of pouch formation. The compound to be tested was suspended in 1% gum tragacanth. Twenty-four hours after the last medication, the pouches were dissected free, and the fluid volume was measured. The inhibition of liquid exudate is a measure of the anti-inflammatory activity.
  • Glycogenic Activity: Mature male rats were bilaterally adrenalectomized 5 days prior to the test. These rats were medicated orally with the test compound for 5 days. Seven hours after the last medication, the rats (which have been fasted overnight) were anesthetized with sodium pentobarbital and a portion of one lobe of the liver was removed and frozen on dry ice for subsequent glycogen determination.
  • The compounds of the invention can be formulated for topical application by solution of dispersion in a conventional pharmaceutically acceptable liquid, cream or ointment base. The effective ingredient is preferably present in a concentration of 0.01% to 5.0% by weight.
  • The compounds of the invention can be formulated for oral administration in tablet or capsule form with conventional excipients. The active ingredient is preferably present in an amount of 1 mg to 100 mg per unit dosage form.
  • The following examples will further illustrate the invention.
    • Example 1 (a) 5-Ethenyl-3-hydroxymethylene-4,4a,7,8-tetrahydro-4a-methyl-2(3H)-naphthalenone.
  • A solution of 50.0 g (0.265 mol) of 5-ethenyl-4, 4a,7,B-tetrahydro-4a-methyl-2(3H)-naphthalenone in 350 mL of tetrahydrofuran was cooled to -5°C. in an ice-methanol bath and stirred under nitrogen while 57.2 g (1.06 mol) of sodium methoxide was added. The resulting mixture was stirred for 30 min at -5°C. and then a solution of 114 mL (1.85 mol) of methyl formate in 100 mL of tetrahydrofuran was added slowly. The mixture was stirred overnight at room temperature and then poured onto a mixture of ice- water (1500 mL) and 6N hydrochloric acid (265 mL). The product was extracted with ether and the combined extracts were washed with water. The dried extract was dried over anhydrous magnesium sulfate and concentrated in vacuo to afford an oil. This oil was triturated with hexane (4 x 250 mL) and the combined triturates were dried over magnesium sulfate and concentrated in vacuo to afford 55.37 g of a red oil, consisting essentially of the above-entitled compound as established by proton NMR (PMR) spectral data.
    • (b) l-Ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahydro-9a-methyl-6H--naphtho[2,3-c]pyrazole (III).
  • 4-Fluorophenylhydrazine hydrochloride (45.85 g, 0.282 mol) and sodium acetate (23.14 g, 0.282 mol) were added to a solution of 55.37 g (0.256 mol) of the product obtained in part (a) above in 225 mL of glacial acetic acid. The mixture was stirred overnight at room temperature and then concentrated in vacuo to afford a semi-solid. This material was suspended in ether (1 L) and filtered to remove sodium chloride. The ether filtrate was washed with water (4 x 250 mL), saturated sodium bicarbonate (until weakly basic) and saturated sodium chloride (100 mL). The extract was dried over anhydrous magnesium sulfate, decolorized with charcoal and concentrated in vacuo to afford an oil. This oil was triturated with 1:2 ether-hexane (3 x 750 mL) to afford 69.58 g of a dark brown oil. An analytical sample was prepared by using high-performance liquid chromatography with 1:3 ether-hexane as solvent. The resulting yellow oil was triturated with pentane to afford l-ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahydro-9a-methyl-6H-naphtho [2,3-c]pyrazole as a yellow solid, m.p. 70-72°C., with a consistent PMR spectrum.
    • Example 2 1,1'-[8-(4-Fluorophenyl)-2,3,4,4a,5,6,11,11a-octahydro-11a-methyl-8H-phenanthro[2,3-c]pyrazole-3,4-diyl]bis[ethanone]
  • (I; R = CH 3).
  • A solution of 20 g (0.065 mol) of l-ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahydro-9a-methyl-6H-naphthol [2,3-c]-pyrazole in 200 mL benzene and 8.07 g (0.072 mol) of 3-hexene-2,5-dione was stirred at reflux for 40 hours under nitrogen. The cooled reaction mixture was filtered through silica gel and concentrated in vacuo. The resultant oil was triturated with ether to afford 7.54 g of a gold solid as a mixture of isomers, m.p. 138-142°C., as determined by PMR spectroscopy. Five g of this mixture of isomers was separated using high-performance liquid chromatography with 1:4 ethyl acetate-hexane. The major isomer was recrystallized from CH2C12-isooctane to afford 3.0 g of 1,1'-[8-(4-fluorophenyl)-2,3,4,4a,5,6,ll,lla-octahydro-lla-methyl-8H-phenanthro[2,3-c]pyrazole-3,4-diyl]bis[ethanone], a white solid, m.p. 157-159°C., a single isomer as determined by PMR spectroscopy.
  • In the endocrine profile determination, Compound I (R = CH3) at a dose level of 5 mg/kg caused a 59% reduction in weight of the thymus, 40% reduction in adrenal weight and 80% reduction in body weight gain as compared with the controls. In the a-tocopherol pouch test, Compound I (R = CH3) was active with ED50 = 23 mg/kg. In the glycogenic activity test, Compound I (R = CH3) at dose levels of 9 and 27 mg/kg/day x 5 produced liver glycogen deposition values of 9.42 + 0.65 and 25.48 + 3.39 mg/g of tissue, respectively, as compared to 1.75 + 0.04 mg/g for the vehicle (ethanol: cottonseed oil 1:9 v/v) alone.
  • By replacing the 3-hexene-2,5-dione in the procedure of Example 2 by a molar equivalent amount of 4-octene-3,6-dione, 5-decene-4,7-dione or 6-dodecene-5,8-dione, it is contemplated that there can be obtained 1,1'-[8-(4-fluorophenyl)-2,3,4,4a,5,6,ll,lla-octahydro-lla- methyl-8H-phenanthro[2,3-c]-pyrazole-3,4-diyl]bis[propanone] (I; R = CH2CH3), 1,1'-[8-(4-fluorophenyl)-2,3,4,4a,5,6,11, 11a-octahydro-11a-methyl-8H-phenanthro[2,3-c]pyrazole-3,4-diyl]bis[butanone] (I; R = CH2CH2CH3), or 1,1'-[8-(4-fluorophenyl)-2,3,4,4a,5,6,ll,lla-octahydro-lla-methyl-8H-phenanthro[2,3-c]pyrazole-3,4-diyl]bis-[pentanone] (I; R = CH2CH2CH2CH3), respectively.
    • Example 3 Diethyl 8-(4-fluorophenyl)-2,3,4,4a,5,6,11,11a-octahydro-11a-methyl-8H-phenanthro[2, 3-c]pyrazole-4,4-dicarboxylate (II; R = CH2CH3).
  • A solution of 25.81 g (0.084 mol) of l-ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahydro-9a-methyl-6H-naphtho [2,3-c]-pyrazole, 18.1 g (0.105 mol) of diethyl methylenemalonate and 500 mg of 1,2,3-benzenetriol in 200 mL of xylene was refluxed for 20 hours. The cooled reaction mixture was filtered through silica gel and concentrated in vacuo to afford 41.93 g of a brown oil. The oil was purified by using high-performance liquid chromatography with 3.97 ethyl acetate-CH2Cl2 followed by recrystallization from methanol to afford 10.98 g of diethyl 8-(4-fluorophenyl)-2,3,4,4a,5,6,ll,lla-octahydro-lla-methyl-8H-phenanthro-[2,3-c]pyrazole-4,4-dicarboxylate as a colorless solid, m.p. 133-135°C. The PMR spectrum was consistent with the assigned structure.
  • In the endocrine profile determination, Compound II (R = CH2CH3) at a dose level of 100 mg/kg caused an 80% reduction in thymus weight, 47% reduction in adrenal weight and 186% reduction in body weight gain as compared with the controls. Compound II (R = CH2CH3) was inactive in the a-tocopherol pouch test at 100 mg/kg.
  • By replacing the diethyl methylenemalonate in the procedure of Example 3 by a molar equivalent amount of dimethyl methylenemalonate, dipropyl methylenemalonate or dibutyl methylenemalonate, it is contemplated that there can be obtained dimethyl 8-(4-fluorophenyl)-2,3,4,4a,5,6, 11,11a-octahydro-11a-methyl-8H-phenanthro[2,3-c]pyrazole-4,4-dicarboxylate (II; R = CH3), dipropyl 8-(4-fluorophenyl)-2,3,4,4a,5,6,ll,lla-octahydro-lla-methyl-8H-phenanthro[2,3-c] pyrazole-4,4-dicarboxylate (II; R = CH2CH2CH3), or dibutyl 8-(4-fluorophenyl)-2,3,4,4a,S,6,ll,lla-octahydro-lla-methyl-8H-phenanthrol[2,3-c]pyrazole-4,4-dicarboxylate (II; R = CH2CH2CH2CH3), respectively.

Claims (8)

1. A compound having the Formula I or II (herein) wherein R and R' are each lower-alkyl.
2. 1,1'-[8-(4-Fluorophenyl)-2,3,4,4a,5,6,11,11a-octahydro-11a-methyl-8H-phenanthro[2,3-c]pyrazole-3,4-diyl]bis-[ethanone], according to claim 1.
3. Diethyl 8-(4-fluorophenyl)-2,3,4,4a,5,6,ll,lla- octahydro-lla-methyl-8H-phenanthro[2,3-c]pyrazole-4,4-dicarboxylate, according to claim 1.
4. A process for preparing a compound according to claim 1, which comprises reacting l-ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahydro-9a-methyl-6H-naphtho[2,3-c]pyrazole with a compound of the formula RCOCH=CHCOR or CH2=C(COOR')2.
5. A process according to claim 4, for preparing the compound according to claim 2, which comprises reacting 1- ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahydro-9a-methyl-6H-naphtho[2,3-c]pyrazole with 3-hexene-2,5-dione.
6. A process according to claim 4, for preparing the compound according to claim 3, which comprises reacting 1- ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahydro-9a-methyl-6H-naphtho[2,3-c]pyrazole with diethyl methylenemalonate.
7. l-Ethenyl-6-(4-fluorophenyl)-3?4,9,9a-tetrahydro-9a-methyl-6H-naphtho[2,3-c]pyrazole having the Formula III (herein).
8. A pharmaceutical composition for treating inflammation in mammals-which comprises an anti-inflammatorily effective amount of a compound according to any one of claims 1-3, and a pharmaceutically acceptable carrier.
EP82108105A 1982-09-02 1982-09-02 Novel polycyclic fused pyrazole compounds useful as antiinflammatory agents and preparation thereof Ceased EP0102404A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP82108105A EP0102404A1 (en) 1982-09-02 1982-09-02 Novel polycyclic fused pyrazole compounds useful as antiinflammatory agents and preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP82108105A EP0102404A1 (en) 1982-09-02 1982-09-02 Novel polycyclic fused pyrazole compounds useful as antiinflammatory agents and preparation thereof

Publications (1)

Publication Number Publication Date
EP0102404A1 true EP0102404A1 (en) 1984-03-14

Family

ID=8189205

Family Applications (1)

Application Number Title Priority Date Filing Date
EP82108105A Ceased EP0102404A1 (en) 1982-09-02 1982-09-02 Novel polycyclic fused pyrazole compounds useful as antiinflammatory agents and preparation thereof

Country Status (1)

Country Link
EP (1) EP0102404A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1542996A2 (en) * 2002-09-20 2005-06-22 Merck & Co., Inc. Octahydro-2-h-naphtho 1,2-f indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
JP2005523254A (en) * 2002-01-22 2005-08-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Non-steroidal ligands for glucocorticoid receptors, compositions thereof and uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307102A (en) * 1981-02-19 1981-12-22 Sterling Drug Inc. Phenanthro[2,3-c]pyrazole
EP0058841A2 (en) * 1981-02-19 1982-09-01 Sterling Drug Inc. Phenylpyrazole compounds useful as anti-inflammatory agents and preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307102A (en) * 1981-02-19 1981-12-22 Sterling Drug Inc. Phenanthro[2,3-c]pyrazole
EP0058841A2 (en) * 1981-02-19 1982-09-01 Sterling Drug Inc. Phenylpyrazole compounds useful as anti-inflammatory agents and preparation thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523254A (en) * 2002-01-22 2005-08-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Non-steroidal ligands for glucocorticoid receptors, compositions thereof and uses
JP2010132672A (en) * 2002-01-22 2010-06-17 Regents Of The Univ Of California Nonsteroidal ligand for glucocorticoid receptor, composition thereof, and use thereof
US7947726B2 (en) 2002-01-22 2011-05-24 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, and compositions thereof
JP4745609B2 (en) * 2002-01-22 2011-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Non-steroidal ligands for glucocorticoid receptors, compositions thereof and uses
EP1542996A2 (en) * 2002-09-20 2005-06-22 Merck & Co., Inc. Octahydro-2-h-naphtho 1,2-f indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
EP1542996A4 (en) * 2002-09-20 2009-11-18 Merck & Co Inc Octahydro-2-h-naphtho 1,2-f indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators

Similar Documents

Publication Publication Date Title
WO1993012081A1 (en) 20-methyl-substituted vitamin d derivates
US4412995A (en) Pentacyclic phenylpyrazole compounds as anti-inflammatory agents
Kupchan et al. Tumor Inhibitors. LXXXI. Structure and partial synthesis of fabacein
US4349558A (en) Anti-inflammatory 8H-phenanthro-[2,3-c]pyrazole derivatives
US4349559A (en) Anti-inflammatory spiro-2H-indene-[2,3']-3H-pyrazolo[4",5":7',6']naphtho[2,1-b]pyran-1,3-dione derivatives
US3946052A (en) 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity
US4307102A (en) Phenanthro[2,3-c]pyrazole
EP0102404A1 (en) Novel polycyclic fused pyrazole compounds useful as antiinflammatory agents and preparation thereof
CA1178965A (en) Polycyclic fused pyrazole compounds useful as anti- inflammatory agents and preparation thereof
EP0058841B1 (en) Phenylpyrazole compounds useful as anti-inflammatory agents and preparation thereof
US3984455A (en) Prostaglandin E1 analogs
US3966745A (en) Vinvamine series cycloalkyl-alkyl esters
US3896156A (en) Dihydroprostaglandin e, analogs
Wells et al. Thietane 1, 1-Dioxides1
EP0443957B1 (en) New 17-spiro substituted steroid compounds, process for their preparation and intermediates of this process, their use as medicines and pharmaceutical preparations containing them
NZ201821A (en) Substituted phenanhro(2,3-c)pyrazole derivatives and pharmaceutical compositions
WO1993013122A1 (en) 3-methylsulphonylhydrazono and 3-oxyimino steroids, a method of preparing them, pharmaceutical preparations containing them and their use in the preparation of drugs
CA1171862A (en) Polycyclic fused pyrazole compounds, useful as anti- inflammatory agents, and preparation thereof
EP0103030A1 (en) Polycyclic fused pyrazole compounds, useful as anti-inflammatory agents, and preparation thereof
US4331663A (en) 4α,5α-Epoxy-3,20-dioxopregnane-2α,16α-dicarbonitrile and intermediates and process for preparation, method of use and compositions thereof
US4235903A (en) 1-Hydroxyalkanamine tetrahydrocarbazoles and cyclopent[b]indoles, compositions and method of use
Razdan et al. Drugs derived from cannabinoids. 3. Sulfur analogs, thiopyranobenzopyrans and thienobenzopyrans
US4785103A (en) 2-oxa- or -aza-pregnane compounds
NZ201822A (en) Spiro-2h-indene(2,3')-3h-pyrazol(4",5":7',6')naptho(2,1-b)pyran-1,3-dione derivatives and pharmaceutical compositions
US4374284A (en) Antiulcer, antiinflammatory, and antiallergic agent comprising as the main ingredient olean-12-ene-3β, 30-diol which is devoid of side effects of glycyrrhetinic acid and a new process for preparation of olean-12-ene-3β, 30-diol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19840824

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19860922

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BELL, MALCOLM RICE